Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms

doi:10.3748/wjg.v25.i48.6928

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 48

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8192)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

588

WORD

282

HTML

3926

Figures (1-3)

385

Tables (1-7)

305

Sum=5486

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

824

Download

1882

Sum=2706

Dec 28, 2019 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 28, 2019; 25(48): 6928-6938
Published online Dec 28, 2019. doi: 10.3748/wjg.v25.i48.6928

Table 1 Clinical and demographic characteristics of the patients

Characteristic	Data
Men/Women	23/16
Age (yr)	59.8 ± 14.2
Hepatitis C virus-RNA (UI/mL)	1.624 × 10³ ± 1.522 × 10³
Hepatitis C virus genotype (n)
1a/1b	4/21
2	5
3	7
4	2
Fibrosis according to Metavir (n)
F0-F2	21
F3-F4	18

Table 2 Health related quality of life domains before and after directly acting antivirals treatment

	Pre DAAs (n = 39)	Post DAAs (n = 39)	P value
Physical functioning	75 ± 27.3	81.9 ± 22.2	0.005
Role limitation physical	68.6 ± 40.4	73.7 ± 36.3	0.35
Bodily pain	63.5 ± 32.2	69.2 ± 27.1	0.19
General health	53.1 ± 21.2	65.9 ± 17.5	< 0.001
Vitality	54.2 ± 20.4	67.2 ± 18,1	< 0.001
Social functioning	66.8 ± 25.4	75.1 ± 20.6	0.03
Role limitation emotional	64.8 ± 39.7	79.4 ± 34.7	0.02
Mental health	60.5 ± 22.2	71.2 ± 18.9	0.002
Physical component summary	62.8 ± 22.7	71.6 ± 21.2	0.002
Mental component summary	59.8 ± 21.9	71.8 ± 19.1	< 0.001

Paired t test, mean ± SD. DAAs: Directly acting antivirals.

Table 3 Neuropsychological tests before and after directly acting antivirals treatment

	Pre DAAs (n = 39)	Post DAAs (n = 39)	P value
TAS-20	49.2 ± 14.2	42.5 ± 12.6	< 0.001
Zung-SDS	41.7 ± 9.3	37.1 ± 8.6	< 0.001
STAI-Y1	39.8 ± 11.9	32.8 ± 7.8	< 0.001
STAI-Y2	41.4 ± 12.2	35.7 ± 9.2	< 0.001

Paired t test, mean ± SD. DAAs: Directly acting antivirals; Zung-SDS: Zung-Self Depression-Rating-Scale; STAI-Y1: Spielberg State-Trait Anxiety Inventory Y1; STAI-Y2: Spielberg State-Trait Anxiety Inventory Y2; TAS-20: Toronto-Alexithymia Scale-20.

Table 4 Prevalence of depression, state and trait anxiety and alexithymia before and after directly acting antivirals treatment, n (%)

	Pre DAAs (n = 39)	Post DAAs (n = 39)	P value
Zung SDS ≥ 50 (no/yes)	8/31 (20)	4/35 (10)	Ns
STAI Y1 ≥ 60 (no/yes)	37/2 (5)	39/0 (0)	Ns
STAI Y2 ≥ 60 (no/yes)	35/4 (10)	39/0 (0)	Ns
TAS-20 ≥ 60 (no/yes)	28/11 (28)	34/5 (13)	Ns

Paired X². DAAs: Directly acting antivirals; Zung-SDS: Zung-Self Depression Rating Scale; STAI-Y1: Spielberg State-Trait Anxiety Inventory Y1; STAI-Y2: Spielberg State-Trait Anxiety Inventory Y2; TAS-20: Toronto-Alexithymia Scale-20; SF36: Short form 36.

Table 5 Correlation matrix between neuropsychological tests and physical component summary and mental component summary of health-related quality of life at basal evaluation

	PCS	MCS	TAS-20	Zung	STAI-Y1	STAI-Y2
PCS	1	0.886^b	-0.343^a	-0.735^b	-0.314^a	-0.471^b
MCS	0.886^b	1	-0.434^b	-0.775^b	-0.534^b	-0.622^b
TAS-20	-0.343^a	-0.434^b	1	0.349^a	0.415^b	0.726^b
Zung	-0.735^b	-0.775^b	0.349^a	1	0.586^b	0.634^b
STAI-Y1	-0. 314^a	-0.534^b	0.415^b	0.586^b	1	0.686^b
STAI-Y2	-0.471^b	-0.622^b	0.726^b	0.634^b	0.686^b	1

^aP < 0.05;

^bP < 0.01. DAAs: Directly acting antivirals; Zung-SDS: Zung-Self Depression-Rating-Scale; STAI-Y1: Spielberg State-Trait Anxiety Inventory Y1; STAI-Y2: Spielberg State-Trait Anxiety Inventory Y2; TAS-20: Toronto-Alexithymia Scale-20; SF-36: Short Form 36; PCS: Physical component summary; MCS: Mental component summary.

Table 6 Correlation matrix between the variations of each neuropsychological test and physical component summary and mental component summary before and after directly acting antivirals treatment

	ΔPCS	ΔMCS	ΔTAS-20	ΔZung	ΔSTAI-Y1	ΔSTAI-Y2
ΔPCS	1	0.752^b	-0.329^a	-0.741^b	-0.218	-0.533^b
ΔMCS	0.752^b	1	-0.494^b	-0.775^b	-0.469^b	-0.654^b
ΔTAS-20	-0.329^a	-0.494^b	1	0.307	0.257	0.539^b
ΔZung	-0.741^b	-0.775^b	0.306	1	0.395^a	0.603^b
ΔSTAI-Y1	-0.218	-0.469^b	0.257	0.395^a	1	0.544^b
ΔSTAI-Y2	-0.533^b	-0.654^b	0.539^b	0.603^b	0.544^b	1

^aP < 0.05;

Table 7 Covariates related to the physical and mental component summary of the Short-Form-36 and to their variation before and after directly acting antivirals treatment, according to the results of the multiple linear regression analysis

	Beta	SE (Beta)	T value	P value
Physical component summary
Zung-SDS	-1.99	0.37	-5.38	< 0.001
Mental component summary
Zung-SDS	-1.53	0.33	-4.62	< 0.001
Δ Physical component summary
Δ Zung-SDS	-1.58	0.32	-4.86	< 0.001
Δ Mental component summary
Δ Zung-SDS	-1.49	0.29	-4.98	< 0.001

SDS: Self Depression Rating Scale.

Citation: Nardelli S, Riggio O, Rosati D, Gioia S, Farcomeni A, Ridola L. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World J Gastroenterol 2019; 25(48): 6928-6938
URL: https://www.wjgnet.com/1007-9327/full/v25/i48/6928.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i48.6928